{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"0.80"},{"groupId":"OG001","spread":"0.21","value":"0.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"558"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"title":"Baseline Induction"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change Baseline, Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.21","value":"0.03"},{"groupId":"OG001","spread":"0.20","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"487"}],"units":"Participants"}],"title":"Change Baseline, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.23","value":"0.04"},{"groupId":"OG001","spread":"0.22","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"468"},{"groupId":"OG001","value":"466"}],"units":"Participants"}],"title":"Change Baseline, Induction Compl"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.23","value":"0.05"},{"groupId":"OG001","spread":"0.22","value":"0.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"377"}],"units":"Participants"}],"title":"Change Baseline, Maint/Obs Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"comment":"NA = NE = Not estimable based on 1 participant evaluated","groupId":"OG001","spread":"NA","value":"-0.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change from Baseline, Maint/Obs Month 12"},{"categories":[{"measurements":[{"comment":"NA = NE = Not estimable based on 1 participant evaluated","groupId":"OG001","spread":"NA","value":"-0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change Baseline, Maint/Obs Completion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"558"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"description":"The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.","dispersionType":"Standard Deviation","groups":[{"description":"Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"MEAN","populationDescription":"The FL ITT population, defined as all randomized participants with follicular histology, where participants were grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)","title":"Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}